Possible Suicidal Risk With Daridorexant, a New Treatment for Insomnia
Source : https://www.psychiatrist.com/jcp/sleep/possible-suicidal-risk-daridorexant-new-treatment-insomnia/
This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher's...
Conclusions: Because hypnotics are commonly prescribed in suicidal and depressed patients, daridorexant should be used very cautiously due to the possible risk of symptomatic aggravation. Further studies would be needed to evaluate its safety of use for psychiatric patients.
Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36473030/
Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder. Daridorexant improves sleep quality without impairing daytime functioning. We assess the safety and efficacy of this novel...
Conclusions: Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly higher incidence of adverse events, including somnolence and fatigue.
Safety and efficacy of daridorexant in the treatment of... : International Clinical Psychopharmacology
databases in SCOPUS, PubMed, Web of Science and the Cochrane library. Seven randomized controlled trials were included in this review, with 2425 participants enrolled. Daridorexant was superior to placebo in...
Clinical considerations for the diagnosis of idiopathic hypersomnia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36401976/
Idiopathic hypersomnia is a sleep disorder of neurologic origin characterized by excessive daytime sleepiness, with sleep inertia, long, unrefreshing naps, and prolonged nighttime sleep being key symptoms in many patients....
Conclusions: In this review, clinical considerations related to the pathogenesis, diagnosis, and management of idiopathic hypersomnia will be discussed, including perspectives from the European Union and United States.